Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor ALL (BLAST)
This study is currently recruiting participants.
Verified November 2012 by Amgen Research (Munich) GmbH
Sponsor:
Amgen Research (Munich) GmbH
Information provided by (Responsible Party):
Amgen Research (Munich) GmbH
ClinicalTrials.gov Identifier:
NCT01207388
First received: September 21, 2010
Last updated: November 20, 2012
Last verified: November 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study is currently recruiting participants. |
|---|---|
| Estimated Study Completion Date: | August 2016 |
| Estimated Primary Completion Date: | February 2014 (Final data collection date for primary outcome measure) |